High expression of PRAME has been identified in various gynecologic tumors, including endometrial carcinomas (82%), uterine serous carcinomas (82%), ovarian clear cell carcinomas (90%), as well as dermatologic tumors such as basal cell carcinomas (62%), primary and metastatic melanoma (80–90%), or uveal melanoma (26–45%) [32,33,34]. The gene discussed is PRAME; the disease is uveal melanoma.